Kevin P. Starr, Director at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 75,000 shares at $109.14 ($7.8M) on 2015-11-11, disclosed to the SEC on 2015-11-13.
Scheduled sale ($7.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.31 | 2,274 | $239K | 3.1% |
| 2 | $106.46 | 4,027 | $429K | 5.5% |
| 3 | $107.39 | 12,606 | $1.4M | 17.4% |
| 4 | $108.23 | 15,499 | $1.7M | 21.5% |
| 5 | $109.14 | 3,094 | $338K | 4.3% |
| 6 | $100.01 | 35,400 |
| $3.5M |
| 45.4% |
| 7 | $101.58 | 1,200 | $122K | 1.6% |
| 8 | $103.01 | 900 | $93K | 1.2% |
| Total | $103.89 avg | 75,000 | $7.8M | 100% |
| Filing → |
| FULC | BUY | 2019-07-22 | $1.3M | — | Filing → |
| SAGE | SELL | 2018-04-19 | $10.0M | — | Filing → |
| MYOK | SELL | 2018-01-05 | $34.3M | — | Filing → |